INNV:OTCQB

Innovus Pharmaceuticals Inc.

Innovus Pharma Inc. is an emerging over the counter (OTC) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men and women’s health and vitality and respiratory diseases. Innovus delivers innovative and uniquely presented and packaged health solutions through its OTC medicines and consumer and health products, which markets directly with commercial partners to primary care physicians, urologists, gynecologists and therapists, and consumers through our on-line channels, retailers and wholesalers. The company is dedicated to being a leader in developing and marketing new OTC and branded abbreviated new drug application products. Innovus is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription to OTC.
INNV:OTCQB

Expert Comments:

A San Diego-based pharmaceutical company that focuses on over-the-counter medications reported strong Q1/17 results and expects to begin marketing a nasal spray by the end of the year.
read more >
Ajay Tandon, SeeThruEquity (5/26/17)
"Innovus Pharmaceuticals Inc. recently released robust top line results in 1Q17. . .revenues rose by 865% to $2.2M in 1Q17 versus $0.2M in 1Q16. . .gross margins remained at attractive levels, at 79%, allowing the company to cash burn and target profitability. . .Innovus issued reiterated its target for $10mn - $15mn in sales for 2017E, which would imply 100% to 200% growth over 2016 revenues of $4.8M. . .we are updating our price target to $0.65. . .Innovus represents a compelling growth company in the healthcare space, with a management team that has demonstrated its ability to execute on sales growth."

Ajay Tandon, SeeThruEquity (11/16/16)
"Innovus Pharmaceuticals Inc. reported 3Q16 results, which showed an improvement in revenues and gross margins on both a sequential and year-over-year basis. Revenues rose by 947% over 3Q15 and more than 80% sequentially to $1.9mn, as compared to $0.2mn in 3Q15 and $1.0mn in 2Q16, respectively. . .we see several potential catalysts for the company over the next year stemming from new products, such as Fluticare™ and Urox, as well as the company potentially reaching recurring adjusted profitability in 2017E. Additionally, management continues to discuss uplisting shares to a national exchange, which could also serve as a catalyst given the potential for increased liquidity and access to more institutional investors."

Amit Tandon, SeeThruEquity (8/15/16)
"We were enthused by 2Q16 results and outlook at Innovus Pharmaceuticals Inc., which clearly showed the company is in growth mode and thus far has been able to integrate the Beyond Human without major setbacks. Innovus reported strong numbers in 2Q16 that seemed to reflect early success with the Beyond Human product line and its sales and marketing platform. . .we were impressed to see Innovus guide to revenues of $5M for 2016, which was well ahead of our estimate of $3M. . .the main swing factors for Innovus outlook are the pace of adoption of new products entering commercialization."

More Expert Comments

Experts Following This Company

Ajay Tandon, CEO – SeeThruEquity
Amit Tandon, Director of Research – SeeThruEquity

The information provided above is from analysts, newsletters, the company and other contributors.

Innovus Pharmaceuticals Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Launching FlutiCare in Q4 2017 which will only be the third nationally branded Fluticasone Propionate Spray in the market
 
Revenue growth potential of over 100% in 2017 and then over 100% again in 2018
 
Continuing to execute on our goal of becoming profitable exiting 2017
catalyst Calendar
Q4
2017
Projected to be Profitable Exiting Q4 2017
Q4
2017
Q4
2018
Innovus Pharmaceuticals Inc. Content